Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

M
M. Lydyard, Peter

University of Westminster
1021 - Transcriptional correlation analysis of the CD180/MD-1 complex and toll-like receptors and signaling lymphocyte activation family receptors in chronic lymphocytic leukemia.
Peter M. Lydyard
Favorite
Møller Pedersen, Lars

Zealand University Hospital
1133 - COVID-19 infection in chronic lymphocytic leukemia (CLL) patients treated with venetoclax: a Danish single-center experience
Lars Møller Pedersen
Favorite
Maňáková, Jiřina
1157 - Significance of TP53 aberrations in context of other pathogenic sequence variants in patients with chronic lymphocytic leukemia in the era of targeted therapy
Jiřina Maňáková
Favorite
Machida, Kazuya

UConn Health
1048 - SH2-Flow: A Multiplex Single Cell Phosphotyrosine Profiling Tool for B-cell Malignancies
Kazuya Machida
Favorite
Macias, Ester

Quirónsalud
1116 - SAFETY PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA UNDERGOING TREATMENT WITH 1ST AND 2ND GENERATION BRUTON TYROSINE KINASE INHIBITORS: MULTICENTRIC REAL-WORLD EXPERIENCE
Ester Macias
Favorite
Mack, Norman

German Cancer Research Center
1057 - Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
Norman Mack
Favorite
Maddocks, Kami

The Ohio State University Comprehensive Cancer Center, Columbus, USA
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Kami Maddocks
Favorite
Madunic, Martina

University Hospital Centre Split
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Martina Madunic
Favorite
Maffei, Rossana

Department of Medical Sciences, Section of Hematology, University of Modena and Reggio Emilia
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Rossana Maffei
Favorite
Mahajan, Neena

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Neena Mahajan
Favorite
Ma, Han

BeiGene USA, Inc.
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Han Ma
Favorite
Maharaj, Kamira

AstraZeneca
1026 - Targeting the pro-inflammatory protein S100-A9 in Chronic Lymphocytic Leukemia
Kamira Maharaj
Favorite
1058 - T-cell Transcriptional and Mitochondrial Fitness Reprogramming in CLL Using PI3Kδ Inhibitors
Kamira Maharaj
Favorite
Mahmoud, Abdurraouf

Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Abdurraouf Mahmoud
Favorite
Mahuad, Carolina
1034 - Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
Carolina Mahuad
Favorite
Maiques-Diaz, Alba

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Alba Maiques-Diaz
Favorite
malý, Josef

Department of Clinical and Social Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University in Prague
1156 - Real-world Effectiveness and Safety of Tixagevimab/Cilgavimab Lower Dosage Regimen in Pre-Exposure Prophylaxis in Patients Undergoing Treatment for Chronic Lymphocytic Leukemia
Josef malý
Favorite
Malcikova, Jitka

1. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic and 2. Central European Institute of Technology (CEITEC), Masaryk University
1010 - The interplay between BcR signaling and the p53 pathway upon DNA damage in primary CLL cells
Jitka Malcikova
Favorite
4004 - Tracking CLL cells with mutation in the TP53 gene using scRNAseq in relapsed/refractory patients
Jitka Malcikova
Favorite
Maloney, David G.

Fred Hutchinson Cancer Research Center
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
David G. Maloney
Favorite
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
David G. Maloney
Favorite
Mancikova, Veronika

1. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic and 2. Central European Institute of Technology (CEITEC), Masaryk University
1010 - The interplay between BcR signaling and the p53 pathway upon DNA damage in primary CLL cells
Veronika Mancikova
Favorite
Mandac-Smoljanovic, Inga

University Hospital Merkur
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Inga Mandac-Smoljanovic
Favorite
Manna, Alak

Department of Cancer Biology, Mayo Clinic
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Alak Manna
Favorite
Mansouri, Larry

Karolinska Institutet
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Larry Mansouri
Favorite
Mantegazza, Francesco
1020 - The mechanical properties of CLL cells are linked to the actin cytoskeleton and are target of BTK inhibitors
Francesco Mantegazza
Favorite
Manzoor, Beenish S.

AbbVie
1143 - The Economic Benefits of Time Off Treatment: Real-World HRU, Costs, and Subsequent Treatment with Fixed Duration Venetoclax among Patients with Chronic Lymphocytic Leukemia
Beenish S. Manzoor
Favorite
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Beenish S. Manzoor
Favorite
Marandi, Ramtin
1053 - Explainable Machine Learning to Identify Chronic Lymphocytic Leukemia Based on Gut Microbiome Data
Ramtin Marandi
Favorite
Marasca, Roberto

Department of Medical Sciences, Section of Hematology, University of Modena and Reggio Emilia
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Roberto Marasca
Favorite
Marella, Narasimha

Loxo@Lilly
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Narasimha Marella
Favorite
Markofski, Melissa

Department of Health and Human Performance, University of Houston
1208 - The HEALTH4CLL study: optimization of behavioral interventions for patients with chronic lymphocytic leukemia
Melissa Markofski
Favorite
Marlton, Paula

Princess Alexandra Hospital
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Paula Marlton
Favorite
Marques, Fernanda

Division of Hematology, UNIFESP.
1227 - Concomitant use of venetoclax 100 mg and ketoconazole to treat CLL in a public center in Brazil
Fernanda Marques
Favorite
Marquet-Palomanes, Juan

Ramon y Cajal University Hospital
1030 - Immunophenotypic Characterization of Richter Syndrome Diffuse Large B-Cell Lymphoma Type and Comparison with the Original Chronic Lymphocytic Leukemia
Juan Marquet-Palomanes
Favorite
Marquez, Maria Elena

Institut Pasteur de Montevideo
1026 - Targeting the pro-inflammatory protein S100-A9 in Chronic Lymphocytic Leukemia
Maria Elena Marquez
Favorite
1032 - Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Maria Elena Marquez
Favorite
1037 - Activation of S100-A9/EMMPRIN axis triggers survival/proliferation pathways in leukemic cells. A novel target for chronic lymphocytic leukemia
Maria Elena Marquez
Favorite
1054 - The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression
Maria Elena Marquez
Favorite
1144 - Patients with unmutated IgHV_1-69; 1-02; 3-30; 4-39 and high expression of AID enzyme need earlier treatment.
Maria Elena Marquez
Favorite
Marr, Alexander
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Alexander Marr
Favorite
Martignetti, Rosalba

Massachusetts General Hospital Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Rosalba Martignetti
Favorite
Martines, Claudio

International Centre for Genetic Engineering and Biotechnology
1038 - Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Claudio Martines
Favorite
Martinez-Laperche, Carolina

Servicio de Hematología, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón
1118 - Similar discriminatory values of IPS-E, AIPSE, and CR0 scores predicting time to first treatment in a large series of unselected patients with early-stage CLL
Carolina Martinez-Laperche
Favorite
Martin-Moro, Fernando
1030 - Immunophenotypic Characterization of Richter Syndrome Diffuse Large B-Cell Lymphoma Type and Comparison with the Original Chronic Lymphocytic Leukemia
Fernando Martin-Moro
Favorite
Martin, Peter

Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
3002 - Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)
Peter Martin
Favorite
Martin-Subero, Jose

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Jose Martin-Subero
Favorite
Maschio, Nilla

Istituto Oncologico Veneto IOV-IRCCS
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Nilla Maschio
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Nilla Maschio
Favorite
Mashima, Kiyomi

Dana-Farber Cancer Institute
1031 - Sex Bias in Mutational Landscape of Chronic Lymphocytic Leukemia: Analysis of Clinical Sequencing Data
Kiyomi Mashima
Favorite
1040 - Exploring the impact of germline ATM mutations in cancer susceptibility and inheritance in chronic lymphocytic leukemia
Kiyomi Mashima
Favorite
1164 - Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)
Kiyomi Mashima
Favorite
Ma, Shuo

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
Shuo Ma
Favorite
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
Shuo Ma
Favorite
Mato, Anthony

Memorial Sloan Kettering Cancer Center
1052 - PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Anthony Mato
Favorite
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Anthony Mato
Favorite
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Anthony Mato
Favorite
Mattiello, Veronica

Hematology Unit, Fondazione IRCCS Ca’ Granda Policlinico
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Veronica Mattiello
Favorite
Mattsson, Agnes

Department of Oncology-Pathology, Karolinska Institutet
1125 - Frequent monitoring in chronic lymphocytic leukemia clinical trials: what is the true value?
Agnes Mattsson
Favorite
Mattsson, Mattias

Department of Hematology, Uppsala University Hospital
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Mattias Mattsson
Favorite
Mauro, Francesca Romana

Department of Translational and Precision Medicine, Hematology unit, 'Sapienza' University
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Francesca Romana Mauro
Favorite
2022 - Prolonged treatment with ibrutinib modulates phenotypic and functional features of immune cell compartments in chronic lymphocytic leukemia
Francesca Romana Mauro
Favorite
Mavani, Heena

Janssen Scientific Affairs, LLC
2025 - Real-world dosing patterns and outcomes in patients with chronic lymphocytic leukemia patients with or without dose adjustment of first-line ibrutinib
Heena Mavani
Favorite
2026 - Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy
Heena Mavani
Favorite
2027 - Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database
Heena Mavani
Favorite
Mayer, Bruce
1048 - SH2-Flow: A Multiplex Single Cell Phosphotyrosine Profiling Tool for B-cell Malignancies
Bruce Mayer
Favorite
Mayer, Jiří

27Department of Internal Medicine - Hematooncology, University Hospital Brno and Medical Faculty MU
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Jiří Mayer
Favorite
Mayer, Jiri

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Jiri Mayer
Favorite
Mazzarello, Andrea

University of Genova
1003 - Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Andrea Mazzarello
Favorite
McAleese, Daniel

Dept of Oncology
3006 - High-risk International Prognostic Score for early asymptomatic CLL (IPS-E) identifies chronic lymphocytic leukaemia at risk of progression to treatment in the OXPLORED study, a prospective observational study for early lymphoproliferative disease
Daniel McAleese
Favorite
McCabe, Chantal

Mayo Clinic
2006 - Impact of nucleotide metabolism on CLL B-cell pathobiology and CLL disease progression
Chantal McCabe
Favorite
McCambridge, Grace

Massachusetts General Hospital Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Grace McCambridge
Favorite
McCarthy, Christine

City of Hope
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Christine McCarthy
Favorite
McEachern, Donna

Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Donna McEachern
Favorite
McGree, Brianne

Massachusetts General Hospital Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Brianne McGree
Favorite
McKay, Pam

Beatson West of Scotland Cancer Centre
3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)
Pam McKay
Favorite
McLaughlin, Eric

The Ohio State University
1158 - A retrospective study evaluating the sequence of BTKi and venetoclax, with a focus on toxicity
Eric McLaughlin
Favorite
McNeely, Samuel C.

Eli Lilly and Company
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Samuel C. McNeely
Favorite
McQuade, Jennifer

MD Anderson Cancer Center
1137 - Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma (AM) in Patients with Concomitant Chronic Lymphocytic Leukemia (CLL)
Jennifer McQuade
Favorite
Mediavilla-Varela, Melanie

H Lee Moffitt Cancer Center & Research Institute
1026 - Targeting the pro-inflammatory protein S100-A9 in Chronic Lymphocytic Leukemia
Melanie Mediavilla-Varela
Favorite
1058 - T-cell Transcriptional and Mitochondrial Fitness Reprogramming in CLL Using PI3Kδ Inhibitors
Melanie Mediavilla-Varela
Favorite
Medina Gil, Daniel

Vall d'Hebron Institute of Oncology (VHIO)
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Daniel Medina Gil
Favorite
Medina, Kay

Mayo Clinic
1134 - High deletion burden identified by whole genome sequencing is associated with enhanced risk in del17p CLL patients
Kay Medina
Favorite
Mekala, Divya

Ascentage Pharma Group Inc.
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Divya Mekala
Favorite
Melamed, Guy
1140 - Pregnancy course of 10 women diagnosed with Chronic Lymphocytic Leukemia
Guy Melamed
Favorite
Melchardt, Thomas

3rd Medical Dept. with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Thomas Melchardt
Favorite
Melero, Carme

Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain/Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain
1152 - Optical genome mapping and fluorescence in situ hybridization is the best combination to identify genomic complexity and TP53 deletions in CLL patients
Carme Melero
Favorite
Melin, Merit

Department of Health Security, Finnish Institute for Health and Welfare
1154 - Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls
Merit Melin
Favorite
Mellink, Clemens

Amsterdam University Medical Centers
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Clemens Mellink
Favorite
Men, Lichuang

Ascentage Pharma (Suzhou) Co., Ltd.
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Lichuang Men
Favorite
Merabet, Fatiha
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Fatiha Merabet
Favorite
4005 - STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR): a randomized phase 2 study from the FILO-CLL group
Fatiha Merabet
Favorite
Meuleman, Nathalie

Department of hematology, Jules Bordet Institute
1036 - Chronic lymphocytic leukemia extracellular vesicles induce the differentiation of monocytes into nurse-like cells
Nathalie Meuleman
Favorite
Mišura, Karla

UH Merkur
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Karla Mišura
Favorite
Miao, Yi

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University
1102 - Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Yi Miao
Favorite
1103 - Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients
Yi Miao
Favorite
1128 - Single-center study of COVID-19 infection in patients with chronic lymphocytic leukemia
Yi Miao
Favorite
1145 - The role of 18F-FDG PET-CT in Richter Transformation and accelerated CLL
Yi Miao
Favorite
1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Yi Miao
Favorite
1228 - Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)
Yi Miao
Favorite
Michie, Alison

University of Glasgow
1022 - FOXO4 is required for the promotion of CLL growth and survival
Alison Michie
Favorite
1027 - B cell receptor-mediated signals modulate rapid FOXO1 upregulation in chronic lymphocytic leukaemia: a role for deubiquitinate proteins?
Alison Michie
Favorite
Miguel García, Cristina

University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca, Salamanca
1161 - ZMYM3 Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients
Cristina Miguel García
Favorite
Mihalic, Jeff
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Jeff Mihalic
Favorite
Mihaylov, Georgi G.

Hematological Clinic NSHATHD
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Georgi G. Mihaylov
Favorite
Mi, Joanna

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Joanna Mi
Favorite
Mikhaleva, Mariia

Dana-Farber Cancer Institute
1031 - Sex Bias in Mutational Landscape of Chronic Lymphocytic Leukemia: Analysis of Clinical Sequencing Data
Mariia Mikhaleva
Favorite
1164 - Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)
Mariia Mikhaleva
Favorite
Mikušková, Eva

Department of Hematooncology 2, National Cancer Institute
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Eva Mikušková
Favorite
Miljak, Antonija

University Hospital Centre Split
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Antonija Miljak
Favorite
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Antonija Miljak
Favorite
Millen, Rosemary

Roche Products Ltd.
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Rosemary Millen
Favorite
Min, Ping

Ascentage Pharma (Suzhou) Co., Ltd.
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Ping Min
Favorite
Miranda, Carolina

Hospital Rey Juan Carlos
1116 - SAFETY PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA UNDERGOING TREATMENT WITH 1ST AND 2ND GENERATION BRUTON TYROSINE KINASE INHIBITORS: MULTICENTRIC REAL-WORLD EXPERIENCE
Carolina Miranda
Favorite
Miranda, Miguel

AstraZeneca
1207 - A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia
Miguel Miranda
Favorite
Misleh, Jamal

Medical Oncology Hematology Consultants
2009 - A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Jamal Misleh
Favorite
Misra, Shrilekha

Division of Hematology, Department of Internal Medicine, The Ohio State University
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Shrilekha Misra
Favorite
1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.
Shrilekha Misra
Favorite
Mitchell, Simon

Brighton and Sussex Medical School
1005 - Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.
Simon Mitchell
Favorite
1023 - Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia
Simon Mitchell
Favorite
Mitrovic, Zdravko

University Hospital Dubrava, School of Medicine University of Zagreb
1019 - Chemokine receptor and adhesion molecule profile on B-cell chronic lymphocytic leukemia (B-CLL) lymphocytes in different lymphoid compartments and changes during BTK inhibitor therapy
Zdravko Mitrovic
Favorite
1130 - Vertebral fractures in patients with B-cell chronic lymphocytic leukemia before and after ibrutinib treatment
Zdravko Mitrovic
Favorite
Mladonicka Pavlasova, Gabriela

CEITEC MU, Brno, Czech Rep.; University Hospital Brno and Faculty of Medicine, Masaryk University
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Gabriela Mladonicka Pavlasova
Favorite
Mocikova, Heidi

Department of Hematology, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University
3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Heidi Mocikova
Favorite
Moga, Esther

Hospital de la Santa Creu i Sant Pau
1104 - Non-Hematological Autoimmune Disorders are frequent in CLL, but are they clinically related? Data from a Single-center Real-Life Cohort
Esther Moga
Favorite
1129 - Incidence and clinical correlates of non-immune cytopenia at diagnosis of chronic lymphocytic leukemia
Esther Moga
Favorite
Mohamed, Hanna

King's College London
1012 - High-dimensional Single-cell Characterisation of the Chronic Lymphocytic Leukaemia Tumour Microenvironment using Imaging Mass Cytometry
Hanna Mohamed
Favorite
Moia, Riccardo

Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Riccardo Moia
Favorite
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Riccardo Moia
Favorite
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Riccardo Moia
Favorite
Moles, Michael
1022 - FOXO4 is required for the promotion of CLL growth and survival
Michael Moles
Favorite
1027 - B cell receptor-mediated signals modulate rapid FOXO1 upregulation in chronic lymphocytic leukaemia: a role for deubiquitinate proteins?
Michael Moles
Favorite
Molla, Vinicius

Hospital Nove de Julho / DASA
1227 - Concomitant use of venetoclax 100 mg and ketoconazole to treat CLL in a public center in Brazil
Vinicius Molla
Favorite
Montalbano, Maria Chiara

Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, University Hospital (A.O.U.) Città della Salute e della Scienza di Torino
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Maria Chiara Montalbano
Favorite
MONTES DE OCA, Mariela Catalina

Institut Paoli Calmettes
1211 - Venetoclax as an Alternative and Effective Treatment in Central Nervous System Involvement of Chronic Lymphocytic Leukemia: Monocentric Experience
Mariela Catalina MONTES DE OCA
Favorite
Montesinos, Pau

Hospital Universitario y Politécnico La Fe
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Pau Montesinos
Favorite
Montillo, Marco

Niguarda Cancer Center, ASST Grande Ospedale Metropolitano
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Marco Montillo
Favorite
Montironi, Chiara

1 Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam institute for Infection and Immunity, Amsterdam, The Netherlands; 2 Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, The Netherlands
1044 - T cells from chronic lymphocytic leukemia patients are not exhausted but show signs of senescence, providing alternative clues for improvement
Chiara Montironi
Favorite
Moore, Jeremiah

University of Rochester Medical Center
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Jeremiah Moore
Favorite
Mora, Alba

Sant Pau Institute for Biomedical Research
1104 - Non-Hematological Autoimmune Disorders are frequent in CLL, but are they clinically related? Data from a Single-center Real-Life Cohort
Alba Mora
Favorite
1117 - EVOLUTION IN THE FRONTLINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: EXPERIENCE FROM ONE EUROPEAN CENTER
Alba Mora
Favorite
1129 - Incidence and clinical correlates of non-immune cytopenia at diagnosis of chronic lymphocytic leukemia
Alba Mora
Favorite
Morabito, Alessia

Vita-Salute San Raffaele University
1042 - LOSS OF IκBε ACCELERATES DISEASE DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
Alessia Morabito
Favorite
Morelli, Francesca

Department of Hematology, University of Florence, Florence, IT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
1040 - Exploring the impact of germline ATM mutations in cancer susceptibility and inheritance in chronic lymphocytic leukemia
Francesca Morelli
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Francesca Morelli
Favorite
Moreno, Carol

Hospital de la Santa Creu i Sant Pau, and the Josep Carreras Leukaemia Research Institute
1104 - Non-Hematological Autoimmune Disorders are frequent in CLL, but are they clinically related? Data from a Single-center Real-Life Cohort
Carol Moreno
Favorite
1117 - EVOLUTION IN THE FRONTLINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: EXPERIENCE FROM ONE EUROPEAN CENTER
Carol Moreno
Favorite
1118 - Similar discriminatory values of IPS-E, AIPSE, and CR0 scores predicting time to first treatment in a large series of unselected patients with early-stage CLL
Carol Moreno
Favorite
1129 - Incidence and clinical correlates of non-immune cytopenia at diagnosis of chronic lymphocytic leukemia
Carol Moreno
Favorite
2028 - Genomic Alterations and Outcomes with Fixed-duration Ibrutinib + Venetoclax: Results from the Phase 3 GLOW Study in Patients with Previously Untreated CLL
Carol Moreno
Favorite
Moric-Peric, Martina

General Hospital Zadar
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Martina Moric-Peric
Favorite
Morillo, Daniel

Hospital Universitario Fundación Jiménez Díaz
1116 - SAFETY PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA UNDERGOING TREATMENT WITH 1ST AND 2ND GENERATION BRUTON TYROSINE KINASE INHIBITORS: MULTICENTRIC REAL-WORLD EXPERIENCE
Daniel Morillo
Favorite
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Daniel Morillo
Favorite
Morris, Lawrence

Blood & Marrow Transplant Group of GA (Northside Hospital)
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Lawrence Morris
Favorite
Morris, Steve

Biomea Fusion
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
Steve Morris
Favorite
Morschhauser, Franck

Centre Hospitalier Universitaire de Lille, University Lille
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Franck Morschhauser
Favorite
Mosca, Antonio

Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Antonio Mosca
Favorite
Moseley, Anna

SWOG Statistical Center
3007 - Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab (VO) versus Delayed Therapy with VO in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study (SWOG S1925; NCT#04269902)
Anna Moseley
Favorite
Mosmann, Tim

University of Rochester Medical Center
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Tim Mosmann
Favorite
Moss, Paul

Institute of Immunology and Immunotherapy, University of Birmingham
1108 - Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia
Paul Moss
Favorite
Motta, Marina

ASST Spedali Civili di Brescia
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Marina Motta
Favorite
Mouawad, Nayla

University of Padua
1016 - DEFACTINIB AFFECTS CHRONIC LYMPHOCYTIC LEUKEMIA CELL SURVIVAL WITH ADDITIVE EFFECT IN COMBINATION WITH BTK INHIBITORS
Nayla Mouawad
Favorite
Mouhssine, Samir

Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Samir Mouhssine
Favorite
Mous, Rogier

Department of Hematology, UMC Utrecht Cancer Center
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Rogier Mous
Favorite
3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)
Rogier Mous
Favorite
Mo, Xioakui

OSU
1046 - Unveiling the Role of Siglec-6 in Regulating B Cell Functions: Implications for Chronic Lymphocytic Leukemia Therapeutics
Xioakui Mo
Favorite
Mraz, Marek

CEITEC MU, Brno, Czech Rep.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University
1006 - Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL
Marek Mraz
Favorite
Mrdeža, Antonia

UHC Sestre Milosrdnice
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Antonia Mrdeža
Favorite
Muñoz Torres, Pau Marc

Vall d'Hebron Institute of Oncology (VHIO)
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Pau Marc Muñoz Torres
Favorite
Muchtar, Eli

Mayo Clinic
1121 - Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with chronic lymphocytic leukemia treated with continuous novel agents
Eli Muchtar
Favorite
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Eli Muchtar
Favorite
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Eli Muchtar
Favorite
1229 - A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)
Eli Muchtar
Favorite
3004 - A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)
Eli Muchtar
Favorite
Muehlenbein, Catherine E.

Loxo@Lilly, Indianapolis
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Catherine E. Muehlenbein
Favorite
Muhowski, Elizabeth

Division of Pharmaceutics, College of Pharmacy, The Ohio State University
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Elizabeth Muhowski
Favorite
Muir, Alex

City of Hope National Medical Center
1210 - A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Alex Muir
Favorite
Mukerji, Ratul
2020 - NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders
Ratul Mukerji
Favorite
Mulder, Tom

Department of oncology-pathology, Karolinska Institutet
1125 - Frequent monitoring in chronic lymphocytic leukemia clinical trials: what is the true value?
Tom Mulder
Favorite
2001 - Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia
Tom Mulder
Favorite
Mulligan, Stephen

Royal North Shore Hospital
1132 - Very low COVID mortality and hospitalization rates in CLL and MBL with repeated vaccination to maximum antibody response
Stephen Mulligan
Favorite
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Stephen Mulligan
Favorite
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Stephen Mulligan
Favorite
Mulvey, Erin

Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital
3002 - Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)
Erin Mulvey
Favorite
Munir, Talha

Clinical Haematology, Leeds Teaching Hospitals NHS Trust
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Talha Munir
Favorite
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Talha Munir
Favorite
2028 - Genomic Alterations and Outcomes with Fixed-duration Ibrutinib + Venetoclax: Results from the Phase 3 GLOW Study in Patients with Previously Untreated CLL
Talha Munir
Favorite
Munné, Marina

Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain/Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain
1152 - Optical genome mapping and fluorescence in situ hybridization is the best combination to identify genomic complexity and TP53 deletions in CLL patients
Marina Munné
Favorite
Murray, Daniel Dawson

Center of Excellence for Health, Immunity, and Infections (CHIP), Rigshospitalet, Copenhagen University Hospital
1146 - Implementing the data-driven CLL-TIM algorithm into an EPIC-based EHR: proof of concept for automated decision support models
Daniel Dawson Murray
Favorite
Murru, Roberta

Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico Armando Businco, ARNAS G. Brotzu
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Roberta Murru
Favorite
1224 - Incidence of arrhythmia in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib: a real-world retrospective analysis from two Italian centers.
Roberta Murru
Favorite
MUTHUSAMY, NATARAJAN

The Ohio State University
1046 - Unveiling the Role of Siglec-6 in Regulating B Cell Functions: Implications for Chronic Lymphocytic Leukemia Therapeutics
NATARAJAN MUTHUSAMY
Favorite